Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Oct 30:13:213.
doi: 10.1186/1471-2474-13-213.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Daniel R Murphy  1 , Lee J Smolen, Timothy M Klein, Robert W Klein
Affiliations
Comparative Study

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Daniel R Murphy et al. BMC Musculoskelet Disord. .

Abstract

Background: This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and glucocorticoid-induced osteoporosis (GIOP). The study's objective was to determine if teriparatide is cost effective against oral bisphosphonates for two large and high risk cohorts.

Methods: A computer simulation model was created to model treatment, osteoporosis related fractures, and the remaining life of PMO and GIOP patients. Natural mortality and additional mortality from osteoporosis related fractures were included in the model. Costs for treatment with both teriparatide and oral bisphosphonates were included. Drug efficacy was modeled as a reduction to the relative fracture risk for subsequent osteoporosis related fractures. Patient health utilities associated with age, gender, and osteoporosis related fractures were included in the model. Patient costs and utilities were summarized and incremental cost-effectiveness ratios (ICERs) for teriparatide versus oral bisphosphonates and teriparatide versus no treatment were estimated.For each of the PMO and GIOP populations, two cohorts differentiated by fracture history were simulated. The first contained patients with both a historical vertebral fracture and an incident vertebral fracture. The second contained patients with only an incident vertebral fracture. The PMO cohorts simulated had an initial Bone Mineral Density (BMD) T-Score of -3.0. The GIOP cohorts simulated had an initial BMD T-Score of -2.5.

Results: The ICERs for teriparatide versus bisphosphonate use for the one and two fracture PMO cohorts were €36,995 per QALY and €19,371 per QALY. The ICERs for teriparatide versus bisphosphonate use for the one and two fracture GIOP cohorts were €20,826 per QALY and €15,155 per QALY, respectively.

Conclusions: The selection of teriparatide versus oral bisphosphonates as a first-line treatment for the high risk PMO and GIOP cohorts evaluated is justified at a cost per QALY threshold of €50,000.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Model Flow for Patient Treatment (Rx) and Fracture Generation (Fx).
Figure 2
Figure 2
One-Way Sensitivity Analysis Tornado Diagram: Teriparatide vs. Bisphosphonate ICERs for the PMO T −3.0/2 Fracture Cohort.
Figure 3
Figure 3
Scatter Plot of Incremental Costs and QALYs for PMO T −3.0/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
Figure 4
Figure 4
Acceptability Curve for PMO T −3.0/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
Figure 5
Figure 5
One-Way Sensitivity Analysis Tornado Diagram: Teriparatide vs. Bisphosphonate ICERs for the GIOP T −2.5/2 Fracture Cohort.
Figure 6
Figure 6
Scatter Plot of Incremental Costs and QALYs for GIOP T −2.5/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
Figure 7
Figure 7
Acceptability Curve for GIOP T −2.5/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment.
See this image and copyright information in PMC

References

    1. Borgström F, Sobocki P, Ström O, Jönsson B. The societal burden of osteoporosis in Sweden. Bone. 2007;40:1602–1609. doi: 10.1016/j.bone.2007.02.027. - DOI - PubMed
    1. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11:669–674. doi: 10.1007/s001980070064. - DOI - PubMed
    1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399–428. doi: 10.1007/s00198-008-0560-z. - DOI - PMC - PubMed
    1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. doi: 10.1056/NEJM200105103441904. - DOI - PubMed
    1. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster J, Stepan JJ, Myers SL, Mitlak BH. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024–2030. doi: 10.1001/archinte.164.18.2024. - DOI - PubMed

Publication types

MeSH terms